Cannabis and psychosis: what is the link?

J Psychoactive Drugs

Faculties of Continuing Education and Graduate Studies, University of Montreal, Quebec, Canada.

Published: June 2007

Growing evidence supports the hypothesis that cannabis consumption is a risk factor for the development of psychotic symptoms. Nonetheless, controversy remains about the causal nature of the association. This review takes the debate further through a critical appraisal of the evidence. An electronic search was performed, allowing to identify 622 studies published until June 1st 2005. Longitudinal studies and literature reviews were selected if they addressed specifically the issues of the cannabis/psychosis relationship or possible mechanisms involved. Ten epidemiological studies were relevant: three supported a causal relationship between cannabis use and diagnosed psychosis; five suggested that chronic cannabis intake increases the frequency of psychotic symptoms, but not of diagnosed psychosis; and two showed no causal relationship. Potential neurobiological mechanisms were also identified, involving dopamine, endocannabinoids, and brain growth factors. Although there is evidence that cannabis use increases the risk of developing psychotic symptoms, the causal nature of this association remains unclear. Contributing factors include heavy consumption, length and early age of exposure, and psychotic vulnerability. This conclusion should be mitigated by uncertainty arising from cannabis use assessment, psychosis measurement, reverse causality and control of residual confounding.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02791072.2007.10399871DOI Listing

Publication Analysis

Top Keywords

psychotic symptoms
12
causal nature
8
nature association
8
causal relationship
8
diagnosed psychosis
8
cannabis
6
cannabis psychosis
4
psychosis link?
4
link? growing
4
growing evidence
4

Similar Publications

Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.

View Article and Find Full Text PDF

Hospitalizations for depressive disorders in Ecuador: An eight-year nationwide analysis of trends and demographic insights.

J Affect Disord

January 2025

School of Medicine, Faculty of Health Sciences, Universidad Técnica de Manabí, Portoviejo, Manabí, Ecuador; Research Institute, Universidad Técnica de Manabí, Portoviejo, Manabí, Ecuador. Electronic address:

Background: Sociodemographic characteristics and limited mental health care access may contribute to higher depression rates in low- and middle-income countries. Aim This study aimed to analyze nationwide depressive disorder hospitalizations in Ecuador.

Methods: We assessed the sociodemographic characteristics, severity, recurrence, and duration of hospitalizations for depressive disorders.

View Article and Find Full Text PDF

Background: People with severe mental illness (SMI) are at increased risk of cardiovascular disease (CVD), and initiatives for CVD risk factor screening in the UK have not reduced disparities.

Objectives: To describe the annual screening prevalence for CVD risk factors in people with SMI from April 2000 to March 2018, and to identify factors associated with receiving no screening and regular screening.

Methods: We identified adults with a diagnosis of SMI (schizophrenia, bipolar disorder or 'other psychosis') from UK primary care records in Clinical Practice Research Datalink.

View Article and Find Full Text PDF

Objectives: There has been limited exploration into the nature and development of psychotic experiences (PEs) in Parkinson's disease (PD). We aimed to comprehensively assess the frequency, severity, and associated distress of paranoia and unusual sensory experiences (USEs) in PD, and to assess what variables are significantly associated with these experiences, focussing on psychological processes central to understanding PEs in non-PD groups.

Method: A questionnaire battery was completed by 369 individuals with PD with a mean age of 66 years and mean time since diagnosis of 5 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!